Sabby Volatility Fund Takes 579,814 Share Stake in Lipella Pharma
Ticker: LIPO · Form: SC 13G · Filed: Jan 3, 2024 · CIK: 1347242
| Field | Detail |
|---|---|
| Company | Lipella Pharmaceuticals Inc. (LIPO) |
| Form Type | SC 13G |
| Filed Date | Jan 3, 2024 |
| Risk Level | medium |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: institutional-ownership, SC-13G, investor-activity
TL;DR
**Sabby Fund just bought 579,814 shares of Lipella Pharma, watch for potential price movement!**
AI Summary
Sabby Volatility Warrant Master Fund, Ltd., a Cayman Islands-based entity, reported beneficial ownership of 579,814 shares of Lipella Pharmaceuticals Inc. common stock as of December 31, 2023. This represents a significant stake, indicating a notable investment by Sabby Management, LLC, which manages the fund. This matters to investors because a large institutional investor taking a substantial position can signal confidence in the company's future prospects or potentially influence its stock price due to the sheer volume of shares held.
Why It Matters
A major institutional investor, Sabby Volatility Warrant Master Fund, Ltd., has disclosed a significant stake in Lipella Pharmaceuticals, which could be interpreted as a vote of confidence and potentially attract other investors.
Risk Assessment
Risk Level: medium — While institutional investment can be positive, the specific reasons for Sabby's investment and their future intentions are not detailed, introducing some uncertainty.
Analyst Insight
Smart investors should monitor Lipella Pharmaceuticals Inc. for potential price movements and research Sabby Management, LLC's investment history to understand their typical strategies with similar stakes.
Key Numbers
- 579,814 — Shares Beneficially Owned (Represents the total number of common stock shares of Lipella Pharmaceuticals Inc. held by Sabby Volatility Warrant Master Fund, Ltd.)
- December 31, 2023 — Date of Event (The date as of which the beneficial ownership was determined for this filing.)
- 53630L100 — CUSIP Number (Unique identification number for Lipella Pharmaceuticals Inc. Common Stock.)
Key Players & Entities
- Sabby Volatility Warrant Master Fund, Ltd. (company) — reporting person and beneficial owner of shares
- Lipella Pharmaceuticals Inc. (company) — the issuer of the securities
- Sabby Management, LLC (company) — the entity filing on behalf of the fund
- Cayman Islands (person) — place of organization for Sabby Volatility Warrant Master Fund, Ltd.
Forward-Looking Statements
- Lipella Pharmaceuticals Inc. stock price may experience increased volatility or upward pressure due to the disclosed institutional investment. (Lipella Pharmaceuticals Inc.) — medium confidence, target: Q1 2024
FAQ
Who is the reporting person in this SC 13G filing?
The reporting person is Sabby Volatility Warrant Master Fund, Ltd., as stated in Item 1 of the filing.
What is the date of the event that required this filing?
The date of the event which required the filing of this statement was December 31, 2023, as indicated on the cover page of the filing.
How many shares of Lipella Pharmaceuticals Inc. common stock does Sabby Volatility Warrant Master Fund, Ltd. beneficially own?
Sabby Volatility Warrant Master Fund, Ltd. beneficially owns 579,814 shares of Lipella Pharmaceuticals Inc. common stock, as reported in Item 6 and 8 of the filing.
What is the place of organization for Sabby Volatility Warrant Master Fund, Ltd.?
The place of organization for Sabby Volatility Warrant Master Fund, Ltd. is the Cayman Islands, as specified in Item 4 of the filing.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(c), as indicated by the 'X' in the appropriate box on the cover page.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on January 3, 2024 by Cayman Islands regarding LIPELLA PHARMACEUTICALS INC. (LIPO).